Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Narendra Patel

Podiatrist, Foot & Ankle Surgery Schaumburg, IL Doctor of Podiatric Medicine

NPI 1578539813 CMS profile 207018

929 W Higgins Rd, Schaumburg, IL 60195

Open in the dashboard

General payments

$180,309

449 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Narendra Patel of Schaumburg, IL is reported in the CMS Open Payments database as having received $180,309 across 449 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34,596 69
2024 General $34,014 70
2023 General $26,842 62
2022 General $41,586 59
2021 General $24,632 64
2020 General $14,356 53
2019 General $4,282 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Narendra Patel
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Narendra Patel were reported at $34,596. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Narendra Patel Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $4,282 $389 $118–$1,406 $163
2020 $14,356 $191 $62–$691 $114
2021 $24,632 $329 $104–$1,341 $132
2022 $41,586 $419 $125–$1,611 $149
2023 $26,842 $377 $128–$1,164 $160
2024 $34,014 $394 $134–$1,168 $164
2025 $34,596 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $161,746 283 payments
  2. Checkpoint Surgical, Inc $5,183 6 payments
  3. Bioness Inc $2,500 1 payment
  4. Wright Medical Technology, Inc. $1,760 19 payments
  5. Paragon 28, Inc. $1,631 9 payments
  6. Zimmer Biomet Holdings, Inc. $1,266 31 payments
  7. Orthofix Medical, Inc. $1,156 25 payments
  8. Fusion Orthopedics USA, LLC $964 12 payments
  9. AxoGen $380 3 payments
  10. Anika Therapeutics, Inc. $367 3 payments
  11. Other $3,356 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $140,606 43 payments
  2. Food and Beverage $21,445 350 payments
  3. Travel and Lodging $15,334 52 payments
  4. Education $2,637 2 payments
  5. Gift $287 2 payments
Products named General payments · program years 2019–2025
  1. VARIAX $37,474 13 payments
  2. ORTHOLOC 2 LAPIFUSE $37,097 32 payments
  3. ORTHOLOC 3DI $36,897 16 payments
  4. HOFFMANN $33,585 26 payments
  5. SALVATION $31,723 28 payments
  6. PROSTEP $26,833 32 payments
  7. GRAVITY SYNCHFIX $16,150 1 payment
  8. CITREFIX $13,641 8 payments
  9. 7 X 23MM CITRELOCK IMPLANT $13,625 6 payments
  10. CARTIVA SYNTHETIC CARTILAGE IMPLANT $11,638 1 payment
  11. Other $74,428 394 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

452

Median for Podiatry: 160

Drug cost

$4,578

Median for Podiatry: $2,368

Branded share of claims

27.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 26 $1,430
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 96 $1,335
Diclofenac Sodium Generic 81 $468
Doxycycline Hyclate Generic 50 $431
Gabapentin Generic 51 $242
Tramadol Hcl Generic 50 $145
Amitriptyline Hcl Generic 16 $141
Cefadroxil Generic 44 $138
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $136
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $85

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$112,801

Of which drugs: $74

Medicare patients

330

Average age 72

Services billed

1,978

225 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 61%
Diabetes 29%
Ischemic heart disease 28%
Depression 19%
Osteoporosis 19%
Chronic kidney disease 17%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $7
$7 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

449 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record